Changeflow GovPing Pharma & Drug Safety Apo-Fluoxetine Recalled Due to Impurities Out o...
Priority review Enforcement Amended Final

Apo-Fluoxetine Recalled Due to Impurities Out of Specification

Favicon for recalls-rappels.canada.ca Health Canada Recalls & Safety Alerts
Filed
Detected
Email

Summary

Health Canada has issued a Type III health product recall for Apo-Fluoxetine 10mg and 20mg capsules by Apotex Inc. due to impurities being out of specification and out of trend. The recall affects retailer-level distribution. Affected lots include VM4608, VM4612 (20mg) and VM4598 (10mg). Patients with affected product should verify their medication and consult healthcare providers before making any changes to their treatment.

What changed

Health Canada has issued a Type III health product recall affecting Apo-Fluoxetine 10mg and 20mg capsules (lots VM4608, VM4612, VM4598) manufactured by Apotex Inc. The recall was initiated because impurities in the affected lots were found to be out of specification and out of trend. The recall depth is limited to retailers.

Healthcare providers and patients should verify whether any affected product is in their possession. Patients are advised to consult their healthcare provider before discontinuing use of the medication, as stopping fluoxetine without medical guidance may pose risks. Apotex Inc. should be contacted for recall procedures. Adverse reactions and quality concerns should be reported to Health Canada. This Type III classification indicates the probability of adverse health consequences is remote.

What to do next

  1. Verify if your product is from affected lots VM4608, VM4612 (20mg) or VM4598 (10mg)
  2. Consult your healthcare provider prior to discontinuing use of the affected product
  3. Report any adverse reactions or health product safety complaints to Health Canada

Archived snapshot

Apr 11, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Health product recall

Apo-Fluoxetine: The impurities are out of specification and out of trend

Brand(s)

Apotex Inc.

Last updated

2026-04-10

Summary

Product Apo-Fluoxetine Issue Health products - Product safety What to do Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concerns.

Affected products

Brand Product Name Market Authorization Dosage Form Strength Lot
Apotex Apo-Fluoxetine 20mg DIN 02216361 Capsule Fluoxetine (Fluoxetine hydrochloride) 20mg VM4608, VM4612
Apotex Apo-Fluoxetine 10mg DIN 02216353 Capsule Fluoxetine (Fluoxetine hydrochloride) 10mg VM4598

Issue

The impurities are out of specification and out of trend in the affected lot.

What you should do

  1. Verify if your product is affected.
  2. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
  3. Contact the recalling firm if you have any questions about the recall.
  4. Report any health product related side effects to Health Canada.
  5. Report any other health product safety complaints to Health Canada.

Additional information

Background

Depth of recall: Retailers

Details

Original published date:

2026-04-10

Alert / recall type Health product recall Category Health products - Drugs Companies

Apotex Inc.

150 Signet Drive

Toronto ON

M9L 1T9

Published by Health Canada Audience General public Healthcare Industry Recall class Type III Recall date

2026-04-10

Identification number RA-81883

Get notified

Receive emails about new and updated recall and safety alerts.

Subscribe

Report a health or safety concern

Get daily alerts for Health Canada Recalls & Safety Alerts

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from Health Canada.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
Health Canada
Filed
April 10th, 2026
Instrument
Enforcement
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
RA-81883

Who this affects

Applies to
Drug manufacturers Healthcare providers Consumers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug recall response Pharmaceutical quality control
Geographic scope
Canada CA

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Clinical Operations
Compliance frameworks
GxP
Topics
Product Safety Healthcare

Get alerts for this source

We'll email you when Health Canada Recalls & Safety Alerts publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!